Sharjah Ruler Launches First 17 Volumes of ‘Historical Corpus of the Arabic Language’
3.11.2021 18:21:00 EET | Business Wire | Press release
A historical cultural feat for the Arab world has been attained, as His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, released the first 17 volumes of the Historical Corpus of the Arabic Language – the first-of-its kind project to chronicle 17 centuries of development in the Arabic language, in the presence of His Highness Sheikh Sultan bin Ahmed Al Qasimi, Crown Prince and Deputy Ruler of Sharjah.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005884/en/
HH Ruler of Sharjah signs the copies of ‘Historical Corpus of the Arabic Language’ at the Sharjah International Book Fair (Photo: AETOSWire)
The Corpus volumes were unveiled by the Sharjah Ruler during the opening ceremony of the 40th edition of the Sharjah International Book Fair (SIBF) on Tuesday (2 November) at Expo Centre Sharjah, in the presence of a host of Arab ministers, presidents of Arabic language academies in the region and several Arabic scholars and researchers. HH Ruler of Sharjah also unveiled the official website of The Historical Corpus of the Arabic Language on this occasion.
In his keynote address, the Sharjah Ruler noted: “Arabic is one of the oldest living languages. We are here to celebrate Arabic language experts who gathered to work for years to document the roots and meanings of the Arabic language alphabet. We have started to work hard and bridge the gaps that existed in the documentation of the language. Finally, the sun has risen on this beautiful Corpus, which is the fruit of the efforts of a number of Arabic language institutions across the region.”
He added: “The role this detailed corpus will play in informing and educating students, researchers, and linguists and even the everyday language enthusiasts will be immense. I am not exaggerating when I say that there has been no other project that has attracted my attention or the attention of the Arab linguist community in our region to the extent that this project has. I am following up on the development of the efforts of everyone involved in this project, and I assure you that in the coming years we will be publishing several more volumes. I thank each and everyone involved in making this project a success.”
The Sharjah Ruler spoke about the online platform and smart phone applications that have been designed to make the Historical Corpus available digitally, and facilitate easy access to these resources from anywhere in the world. He also signed the copies of the first edition of the Historical Corpus of the Arabic Language at the SIBF 2021 opening ceremony.
The first volumes of the corpus are dedicated to the first five Arabic letters: the Hamza, ba, ta, tha and jeem and outline their evolution throughout the pre-Islamic period, the Islamic era from 1 AH to 132 AH, the Abbasid Caliphate from 133 AH to 656 AH, and the modern-day era from 1214 AH to date.
Dedicated website
The website dedicated to the Historical Corpus of the Arabic Language will offer scholars, linguists, researchers and language enthusiasts access to the 17 volumes of the corpus from anywhere in the world.
Champions of the Arabic language from across the region joined hands
The corpus has seen the collaboration of hundreds of researchers and linguists, editors and experts from 10 Arabic language academies across the Arab world, under the supervision of the Union of Arab Scientific Language Academies in Cairo, Egypt, and with the Arabic Language Academy in Sharjah managing the project’s executive committee. The corpus relies on a database of sources collected and digitised over the last four years, comprising 20,000 Arabic books, manuscripts, sources, and historical documents, including old inscriptions and archaeological finds.
The Historical Corpus of the Arabic Language is dedicated to providing key information about the history of Arabic lexicon, the original root of each word and all other words that are derived from the root with their vocal and phonetic changes. It traces the history of a given word and identifies the first user and evolution of that word from pre-Islamic Arabia all the way to the modern time. In this respect, it is different from any other dictionary because it cites living verses of the Holy Quran and Hadith of the Prophet, peace be upon him.
It also reveals the development of Arabic idioms and expressions through the centuries, and documents the entry of new words into Arabic language, lists words that are no longer used, and explains the reasons why. Besides, the corpus reviews the development of arts and sciences that directly relate to linguistics including grammar, morphology, philology, phonetics, rhetoric, rhyme, and so on.
It also offers comparative lexical reviews on Arabic and the influence it had on other Semitic languages such as Hebrew, Akkadian, Syriac, Abyssinian, and Amharic. An expert committee outlined the similarities and differences between Arabic words and the equivalent words in those languages, citing examples and documenting the bibliography and reference books that were used in the project.
Several senior officials were present during the launch, including Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Tolerance and Coexistence; Bodour Al Qasimi, President of the International Publishers Association; Sheikha Hoor Al Qasimi, President of the Sharjah Art Foundation; Sheikh Khalid bin Issam Al Qasimi, Chairman of the Department of Civil Aviation in Sharjah; Sheikh Salem bin Abdulrahman Al Qasimi, Chairman of the Sharjah Ruler's Office; Sheikha Nawar bint Ahmed Al Qasimi, Director, SAF; Abdul Rahman bin Mohammad Al Owais, UAE Minister of Health and Prevention.
The launch of the corpus’s 17 volumes was also witnessed by Dr. Salah Fadl, President of the Arab Language Academy in Cairo; Dr. Mamoun Wajeeh, Scientific Manager of the Historical Corpus of the Arabic Language; Dr. Abdulhamid Madkour, Secretary General of the Union of Arab Scientific Language Academies, and Secretary-General of the Arabic Language Academy in Cairo.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005884/en/
Contact information
Hussain Al Mulla
Email: hussain.almulla@sgmb.ae
Phone: +97156 3980067
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
